



What do these results mean for people living with multiple myeloma?

People living with multiple myeloma that had come back (relapsed) or stopped responding to treatment (refractory), also called RRMM, and with extramedullary disease had a better response when treated with talquetamab (Tal) + teclistamab (Tec) than either therapy alone. Side effects of the combination were not worse than either therapy alone. These results support Tal + Tec as a promising treatment option for people with RRMM and extramedullary disease.



What was the purpose of this study?

- To evaluate the effectiveness and safety of combining 2 drugs, Tal and Tec, in treating people living with RRMM and extramedullary disease, an aggressive form of myeloma with poor outcomes and no standard treatment



Who was in the study and how was the study carried out?

- There were 90 participants with RRMM and extramedullary disease
- People received Tal + Tec every other week for 4–6 months and then could receive Tal + Tec monthly
- The main goal was to see how many people had their number of cancer cells decreased by 50% or more

Primary objective:	Secondary objectives:	
• The percentage of people whose number of cancer cells decreased by 50% or more (had a partial response or better)	• Length of time that the cancer cells remained decreased by 50% or more	• Time patients survived since treatment started
	• Time since treatment started until the return, growth, or spread of cancer	• Frequency and severity of side effects



People with RRMM who previously received 3 standard treatments for multiple myeloma (proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody)

Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed or Refractory Multiple Myeloma and Extramedullary Disease: RedirecTT-1

Saad Z Usmani¹, María-Victoria Mateos², Jing Christine Ye³, Shebli Atrash⁴, Hila Magen⁵, Hang Quach⁶, Michael P Chu⁷, Suzanne Trudel⁸, Joshua Richter⁹, Paula Rodríguez-Otero¹⁰, Hun Chuah¹¹, Moshe Gatt¹², Eva Medvedova¹³, Shahzad Raza¹⁴, Dok Hyun Yoon¹⁵, Tadao Ishida¹⁶, Jeffrey V Matous¹⁷, Koichi Onodera¹⁸, Emma Scott¹⁹, Christoph Heuck¹⁹, Payal Thakkar²⁰, Mariacristina Festa²¹, Lin Huang¹⁹, Shaji Kumar²², Yaël C Cohen²³


¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain; ³MD Anderson Cancer Center, University of Texas, Houston, TX, USA; ⁴Levine Cancer Institute-Atrium Health, Charlotte, NC, USA; ⁵Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; ⁶University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia; ⁷Alberta Health Services, Edmonton, AB, Canada; ⁸Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁹Mount Sinai Medical Center, New York, NY, USA; ¹⁰Cancer Center Clínica Universidad de Navarra, Cima, Pamplona, Spain; ¹¹Royal Perth Hospital, Perth, WA, Australia; ¹²Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel; ¹³Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA; ¹⁴Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; ¹⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ¹⁶Japanese Red Cross Medical Center, Tokyo, Japan; ¹⁷Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO, USA; ¹⁸Tohoku University Hospital, Sendai shi, Miyagi, Japan; ¹⁹Johnson & Johnson, Spring House, PA, USA; ²⁰Johnson & Johnson, Raritan, NJ, USA; ²¹Johnson & Johnson, Leiden, Netherlands; ²²Mayo Clinic Rochester, Rochester, MN, USA; ²³Tel Aviv Sourasky (Ichilov) Medical Center, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel



What were the results?


How many people had a response with Tal + Tec?

Most people with RRMM and extramedullary disease who took Tal + Tec responded to treatment and had a deeper response compared with either therapy alone



64% of people on Tal + Tec maintained their response at 12 months

How many people were alive without their cancer growing or spreading at 12 months?




61%

6 out of 10 people on Tal + Tec were alive without their cancer progressing at 1 year

Among people whose cancer did worsen or who died, the typical time before the cancer worsened or the patient died was 15 months

How many people were alive at 12 months?



7.5 out of 10 people on Tal + Tec were alive 12 months after starting Tec + Tal therapy

The typical survival time could not be measured because more than half of people were alive, which suggests the treatment may be helping people live longer

Most common adverse events

GPCR5D-related

Any-grade
Grade 3/4

Taste changes



79%
NA

Infections



79%
31%

Immune system overreaction



78%
0%

Low white blood cell count



72%
62%

Non-rash skin changes



69%
0%

Nail changes



56%
0%

Weight decrease



53%
11%

Side effects with Tal + Tec were similar to each therapy alone; incidence and severity of side effects were not worse with the Tal + Tec combination

NA, not applicable – the scale for measuring taste changes only includes grade 1 and 2.

Glossary of terms

Multiple myeloma	A type of blood cancer that affects plasma cells in the bone marrow; relapsed or refractory multiple myeloma (RRMM) is when it returns or stops responding to treatment	Talquetamab	A bispecific antibody that targets a protein on myeloma cells called GPCR5D and a protein on white blood cells called CD3 and is used in the treatment of RRMM	Teclistamab	A bispecific antibody that targets a protein on myeloma cells called BCMA and a protein on white blood cells called CD3 and is used in the treatment of RRMM
Bispecific antibody	An antibody that binds to 2 different targets at the same time and is used in cancer treatment	Extramedullary disease	A form of myeloma that spreads outside the bone marrow to other parts of the body, such as soft tissues or the liver	Grade 3 or 4 adverse events	Severe or life-threatening side effects that happen during or after treatment Grade 3 = severe; Grade 4 = life-threatening